心力衰竭中的矿物质皮质类受体抗剂:个体患者水平的元分析
Pardeep S Jhund1, Atefeh Talebi1, Alasdair D Henderson1
1BHF Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
Lancet (London, England)
|September 4, 2024
概括
矿物质皮质类受体对抗剂 (MRA) 对心力衰竭和减少排泄率 (HFrEF) 的患者有益. 对于轻微减少或保留喷射分数 (HFmrEF/ HFpEF) 的心力衰竭,类固醇MRA效果低于非类固醇MRA.
科学领域:
- 心脏病学
- 药理学
- 临床试验
背景情况:
- 矿物质皮质类受体抗剂 (MRA) 是已知的心力衰竭治疗方法.
- 对于心力衰竭和轻微减少的喷射分数 (HFmrEF) 或心力衰竭与保存的喷射分数 (HFpEF) 的患者,MRA 的疗效仍然不太清楚.
- 这一元分析调查了MRA在心力衰竭中排放分数的有效性.
研究的目的:
- 评估MRA对心力衰竭患者心血管结果的影响.
- 将HFrEF患者与HFmrEF或HFpEF患者的MRA疗效进行比较.
- 评估MRA的安全性,包括电解质和血压变化.
主要方法:
- 在四项随机对照试验 (RALES,EMPHASIS- HF,TOPCAT,FINEARTS- HF) 的个体患者层面的分析.
- 主要结局:至第一次心力衰竭住院或心血管死亡的时间.
- 二次结果:主要结果的组成部分,全因死亡和安全参数 (血清肌,EGFR,,血压).
主要成果:
- MRA显著降低了心血管死亡或心力衰竭住院的风险 (HR 0. 77).
- 与HFmrEF/ HFpEF (HR 0. 87) 相比,HFrEF (HR 0. 66) 的有效性更大,具有显著的异质性 (p=0. 0012).
- 类固醇MRA对HFrEF有好处,而非类固醇MRA对HFmrEF/ HFpEF对住院风险有好处. 超血症的风险增加了一倍,但严重的超血症并不常见.
结论:
- 在HFrEF患者中,MRA有效减少心血管死亡或心力衰竭住院.
- 非类固醇MRA在HFmrEF/ HFpEF患者中表现出有效性,而类固醇MRA在HFrEF患者中更有效.
- 使用MRA与高血症的风险增加有关,需要仔细监测.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
404
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
404
01:22Heart Failure Drugs: Diuretics
352
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
352
01:22Heart Failure Drugs: β-Blockers
322
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
322
01:26Heart Failure Drugs: Inotropic Agents
545
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
545
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
614
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
614
01:25Antihypertensive Drugs: Direct Renin Inhibitors
511
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
511